Slingshot members are tracking this event:

Onconova Therapeutics, Inc. Receives Notice of Termination for Convenience from Baxalta for rigosertib

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
ONTX Community voting in process
BXLT Community voting in process

Additional Information

Additional Relevant Details The INSPIRE trial is a global, multi-center, randomized controlled study to assess the efficacy and safety of IV rigosertib in HR-MDS patients under 80 years of age who had progressed on, or failed to respond to, or relapsed after previous treatment with HMAs.  For these patients who have failed treatment with an HMA, there is a significant unmet medical need because there is no alternative available therapy.  The INSPIRE trial is now enrolling higher-risk MDS patients who have failed all approved therapies, at multiple U.S. sites, and the Company is initiating additional clinical centers in the U.S. and abroad.
Until the August 30, 2016 termination date, Baxalta is obligated to provide various financial contributions, including 50 percent of the clinical trial costs for the INSPIRE trial up to a specified cap. Onconova is currently in discussions with Baxalta regarding the amount of financial support sufficient to complete the INSPIRE trial that was commenced in December following consultation with Baxalta.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 03, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Notice Of Termination, Cancer, Rigosertib, Inspire Trial, Intravenous, Higher-risk Myelodysplastic Syndromes, Hr-mds, Hma, Hypomethylating Agent Therapy